drugset / Trial / NCT00002195

A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients

NCT00002195

Phase 3 Completed 290 enrolled Glaxo Wellcome
Parallel-groupTreatment

Summary

The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Amprenavir Other / unclassified
Background Lamivudine Other / unclassified
Background Zidovudine Small molecule